Study of Carfilzomib in Multiple Myeloma Relapsed After High-dose Melphalan With Autologous Stem Cell Support

Multiple Myeloma Clinical Trial

— CARFI  

Official title:

Phase II Study of Carfilzomib-cyclophosphamide-dexamethasone and High-dose Melphalan (HDT) Followed by Randomization Between Observation or Maintenance With Carfilzomib and Dexamethasone in Patients With Relapsed Multiple Myeloma After HDT

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT02572492
• Other study ID #: NMSG#20/13
• Secondary ID: 2013-003789-15
• Status: Active, not recruiting
• Phase: Phase 2
• Start date: January 2015
• Est. completion date: April 2019

Study information

• Verified date: August 2018
• Source: Aalborg Universitetshospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study evaluates induction therapy with carfilzomib-cyclophosphamide-dexamethasone before salvage high-dose melphalan with autologous stem cell support (HDT) in multiple myeloma patients with relapse after HDT done at diagnosis. In addition, the study evaluates the effect of maintenance therapy after salvage HDT in multiple myeloma. After salvage HDT half of the patients receive maintenance therapy with carfilzomib/dexamethasone while the other half are observed without maintenance therapy.

Description:

The survival in younger myeloma patients improved in the nineties with the introduction of high-dose melphalan with autologous stem cell support (HDT) and despite the emergence of novel therapies HDT remains a keystone in myeloma treatment. However, all patients will eventually experience relapse after HDT performed at diagnosis. Eligible patients with late relapse are considered for salvage HDT. The duration of response after salvage HDT is in most studies reported to be approximately half the length of the response after initial HDT. The choice of induction treatment before HDT might affect the outcome after the induction therapy as well as the outcome after the HDT. In other settings the novel proteasome inhibitor Carfilzomib has showed superiority to the first-in-class proteasome inhibitor bortezomib. In addition, carfilzomib has a favourable profile of side effects. Thus, the aim of this phase 2 study is to evaluate induction therapy with carfilzomib-cyclophosphamide-dexamethasone before salvage HDT. The primary end-point in this part of the study is comparison of time to progression after the initial HDT and time to progression after salvage HDT when four series of carfilzomib-cyclophosphamide-dexamethasone are used as induction therapy. In the study Carfilzomib is also included in the conditioning regimen with administration of Iv carfilzomib 27 mg/sqm on day -2 and -1. The standard conditioning regime consists of Iv melphalan 200 mg/sqm on day -2 and reinfusion of at least 2.0 x 10m CD34+ stem cells/kg body weight on day 0.

The purpose of maintenance therapy in multiple myeloma is to prolong the time to progression of disease. There are limited data on the impact of maintenance therapy after salvage HDT. Another important aim of the study is therefore to evaluate the effect of carfilzomib/dexamethasone given every other week compared to observation without maintenance therapy. This part of the study starts two months after HDT. The randomization is stratified according to relapse 1 - 2 years or > 2 years after HDT, ISS stage and standard versus high-risk cytogenetics. The primary end-point of this part of the study is comparison of time to progression in carfilzomib-dexamethasone maintenance arm and in the observational arm. Patients will continue on maintenance therapy/observation until progression, end of study or fulfil standard criteria for discontinuation of treatment according to the protocol.

The study will include 200 patients with relapse of multiple myeloma more than one year after initial HDT. It is a prerequisite that the patients have at least 2.0 x 10m CD34+ stem cells/kg body weight saved in the freezer. The study is conducted by the Nordic Myeloma Study Group (NMSG) at clinics in Denmark, Sweden, Norway, Finland and Lithuania. The first patient was included in January 2015 and enrolment is expected to continue until December 2017. The study ends when the last included patient has been followed for 9 months after randomization.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 200
• Est. completion date: April 2019
• Est. primary completion date: April 23, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Myeloma diagnosis according to IMWG criteria

• First treatment demanding relapse after HDT according to IMWG criteria

• More than 2.0 x 10m CD34+ stem cells / kg body weight in the freezer for stem cell support

• Signed informed consent given prior to any study related activities have been performed

• Age > 18 years

Exclusion Criteria:

Demographic

• Allogeneic transplantation scheduled as a part of the treatment

• Treatment demanding relapse less than one year after HDT

• Myeloma treatment after the first HDT, except radiotherapy, bisphosphonates, denosumab and corticosteroids less than 6 days for symptom control

• Patients not having received HDT as first line treatment

• Previous treatment with carfilzomib

• Expected survival of less than six months

• Performance status (WHO) = 3

Laboratory

• Serum M-component < 5 g/l and urine M-component < 200 mg/l

• Any of the following laboratory abnormalities:

• Absolute neutrophil count (ANC) < 1.0 × 109/L

• Hemoglobin < 5 mmol/L (<80 g/L) (prior RBC transfusion or recombinant human erythropoietin use is permitted)

• Platelet count < 50 × 109/L (< 30 × 109/L if myeloma involvement in the bone marrow is > 50%)

• Serum ALT or AST > 3.5 times the upper limit of normal and serum direct bilirubin > 34 µmol/L (2 mg/dL)

• Creatinine clearance (CrCl) < 15 mL/minute, either measured or calculated using a standard formula

Concurrent conditions

• Concurrent disease making treatment with carfilzomib, cyclophosphamide or dexamethasone unsuitable

• Significant neuropathy (Grades 3-4, or Grade 2 with pain) within 14 days prior to enrolment

• Major surgery within 21 days prior to enrolment

• Acute active infection requiring treatment

• Known or suspected hypersensitivity or intolerance to melphalan, dexamethasone or Captisol® (a cyclodextrin derivative)

• Uncontrolled or severe cardiovascular disease including myocardial infarction within 6 months of enrolment, NYHA Class III or IV heart failure, uncontrolled angina, clinically significant pericardial disease, uncontrolled severe arrhythmias, or cardiac amyloidosis

• LVEF <40%, determined by 2-D transthoracic echocardiogram (ECHO) or Multigated Acquisition Scan (MUGA)

• Pleural effusions requiring thoracentesis or ascites requiring paracentesis within 14 days prior to enrolment

• Serious hepatic disorder, including active hepatitis B or C infection

• Other serious medical or psychiatric illness likely to interfere with participation in this clinical study

• Use of any investigational agents or experimental medical device within 28 days prior to enrolment into the study

Ethical/other

• Pregnant or lactating females

• Females of childbearing potential must agree to ongoing pregnancy testing and to practice contraception

• Male subjects must agree to practice contraception

Related Conditions & MeSH terms

• Multiple Myeloma
• Neoplasms, Plasma Cell

Intervention

Drug:
• Induction with CAR-CY-DEX and conditioning with carfilzomib and highdose melphalan
All patients entering the study receive four series of CAR-CY-DEX (Cycle 1 with iv carfilzomib 20 mg/sqm on days 1 and 2, and iv carfilzomib 36 mg/sqm on days 8, 9, 15 and 16. Cycle 2 - 4 with iv carfilzomib 36 mg/sqm on days 1, 2, 8, 9, 15 and 16. P.o. cyclophosphamide 300 mg/sqm on days 1, 8 and 15 and p.o. dexamethasone 20 mg on days 1, 2, 8, 9, 15 and 16 in each 28-days series) Subsequently all patients receive the conditioning regimen: Iv carfilzomib 27 mg/sqm on day -2 and -1 Iv melphalan 200 mg/sqm on day -2 > 2.0 m CD34+ stem cells/kg body weight on day 0
• Carfilzomib/dexamethasone maintenance
Maintenance therapy two months after salvage HDT with iv carfilzomib 27 mg/sqm every second week and p.o. dexamethasone 20 mg every second week. The maintenance dose of carfilzomib will be escalated to 56 mg/sqm after 4 weeks provided acceptable side effects.
• Observation without carfilzomib/dexamethasone maintenance
Observation without carfilzomib/dexamethasone maintenance

Locations

Country	Name	City	State
Denmark	Aalborg University Hospital	Aalborg
Finland	Turku University Hospital	Turku
Lithuania	Vilnius University hospital "Santariskiu Clinics"	Vilnius
Norway	Oslo University Hospital	Oslo
Sweden	Skåne University Hospital	Lund

Sponsors (2)

Lead Sponsor	Collaborator
Henrik Gregersen	Nordic Myeloma Study Group

Countries where clinical trial is conducted

Denmark,  Finland,  Lithuania,  Norway,  Sweden, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Comparison of time to progression after high-dose melphalan with stem cell support (HDT) performed at diagnosis and time to progression after a salvage HDT combined with carfilzomib-cyclophosphamide-dexamethasone		3 years
Primary	Comparison of time to progression between carfilzomib-dexamethasone maintenance and observation in patients treated with salvage HDT.		3 years
Secondary	Adverse events assessed by CTCAE v4.0 in carfilzomib-cyclophosphamide-dexamethasone induction regime and carfilzomib as part of the high-dose melphalan conditioning		5 months
Secondary	Response rates of carfilzomib-cyclophosphamide-dexamethasone induction therapy and HDT		5 months
Secondary	Time to marrow regeneration (neutrophil- and platelet recovery) after the HDT		3 weeks
Secondary	Adverse events assessed by CTCAE v4.0 in maintenance treatment with carfilzomib-dexamethasone		3 years
Secondary	Comparison of overall survival between carfilzomib-dexamethasone maintenance and observation in patients treated with a salvage HDT		3 years
Secondary	Quality of life assessed by EORTC QLQ-MY20 and EORTC QLQ-C30		3 years